Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.

臺大醫院-腫瘤醫學部;臺大醫學院-腫瘤醫學研究所;臺大醫學院-癌症研究中心;Papadimitrakopoulou, VassilikiVassilikiPapadimitrakopoulouPatnaik, AmitaAmitaPatnaikBorghaei, HosseinHosseinBorghaeiStevenson, JamesJamesStevensonGandhi, LeenaLeenaGandhiGubens, Matthew A.Matthew A.GubensYang, James Chih-HsinJames Chih-HsinYangSequist, Lecia V.Lecia V.SequistGe, Joy YangJoy YangGeBourque, JenniferJenniferBourqueBachman, Robert D.Robert D.BachmanIm, EllieEllieImGadgeel, Shirish M.Shirish M.Gadgeel2017-06-272018-07-092017-06-272018-07-092015http://ntur.lib.ntu.edu.tw//handle/246246/280134[SDGs]SDG3Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.